Positron Emission Tomography Assessments of Phosphodiesterase 10A in Patients With Schizophrenia.
MRS
PDE10A
PET
cognition
glutamate
striatum
Journal
Schizophrenia bulletin
ISSN: 1745-1701
Titre abrégé: Schizophr Bull
Pays: United States
ID NLM: 0236760
Informations de publication
Date de publication:
03 05 2023
03 05 2023
Historique:
medline:
4
5
2023
pubmed:
3
12
2022
entrez:
2
12
2022
Statut:
ppublish
Résumé
Phosphodiesterase 10A (PDE10A) is a highly expressed enzyme in the basal ganglia, where cortical glutamatergic and midbrain dopaminergic inputs are integrated. Therapeutic PDE10A inhibition effects on schizophrenia have been reported previously, but the status of this molecule in the living patients with schizophrenia remains elusive. Therefore, this study aimed to investigate the central PDE10A status in patients with schizophrenia and examine its relationship with psychopathology, cognition, and corticostriatal glutamate levels. This study included 27 patients with schizophrenia, with 5 antipsychotic-free cases, and 27 healthy controls. Positron emission tomography with [18F]MNI-659, a specific PDE10A radioligand, was employed to quantify PDE10A availability by measuring non-displaceable binding potential (BPND) of the ligand in the limbic, executive, and sensorimotor striatal functional subregions, and in the pallidum. BPND estimates were compared between patients and controls while controlling for age and gender. BPND correlations were examined with behavioral and clinical measures, along with regional glutamate levels quantified by the magnetic resonance spectroscopy. Multivariate analysis of covariance demonstrated a significant main effect of diagnosis on BPND (p = .03). A posthoc test showed a trend-level higher sensorimotor striatal BPND in patients, although it did not survive multiple comparison corrections. BPND in controls in this subregion was significantly and negatively correlated with the Tower of London scores, a cognitive subtest. Striatal or dorsolateral prefrontal glutamate levels did not correlate significantly with BPND in either group. The results suggest altered striatal PDE10A availability and associated local neural dysfunctions in patients with schizophrenia.
Sections du résumé
BACKGROUND AND HYPOTHESIS
Phosphodiesterase 10A (PDE10A) is a highly expressed enzyme in the basal ganglia, where cortical glutamatergic and midbrain dopaminergic inputs are integrated. Therapeutic PDE10A inhibition effects on schizophrenia have been reported previously, but the status of this molecule in the living patients with schizophrenia remains elusive. Therefore, this study aimed to investigate the central PDE10A status in patients with schizophrenia and examine its relationship with psychopathology, cognition, and corticostriatal glutamate levels.
STUDY DESIGN
This study included 27 patients with schizophrenia, with 5 antipsychotic-free cases, and 27 healthy controls. Positron emission tomography with [18F]MNI-659, a specific PDE10A radioligand, was employed to quantify PDE10A availability by measuring non-displaceable binding potential (BPND) of the ligand in the limbic, executive, and sensorimotor striatal functional subregions, and in the pallidum. BPND estimates were compared between patients and controls while controlling for age and gender. BPND correlations were examined with behavioral and clinical measures, along with regional glutamate levels quantified by the magnetic resonance spectroscopy.
STUDY RESULTS
Multivariate analysis of covariance demonstrated a significant main effect of diagnosis on BPND (p = .03). A posthoc test showed a trend-level higher sensorimotor striatal BPND in patients, although it did not survive multiple comparison corrections. BPND in controls in this subregion was significantly and negatively correlated with the Tower of London scores, a cognitive subtest. Striatal or dorsolateral prefrontal glutamate levels did not correlate significantly with BPND in either group.
CONCLUSIONS
The results suggest altered striatal PDE10A availability and associated local neural dysfunctions in patients with schizophrenia.
Identifiants
pubmed: 36458958
pii: 6865142
doi: 10.1093/schbul/sbac181
pmc: PMC10154699
doi:
Substances chimiques
Phosphoric Diester Hydrolases
EC 3.1.4.-
Glutamates
0
PDE10A protein, human
EC 3.1.4.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
688-696Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.
Références
J Nucl Med. 2014 Aug;55(8):1297-304
pubmed: 24898025
Schizophr Res. 2004 Jun 1;68(2-3):283-97
pubmed: 15099610
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Feb 4;65:49-53
pubmed: 26334687
J Pharmacol Sci. 2010;114(1):6-16
pubmed: 20716858
Dialogues Clin Neurosci. 2016 Mar;18(1):7-21
pubmed: 27069376
J Neurosci. 2015 Jul 01;35(26):9615-21
pubmed: 26134644
J Chem Neuroanat. 2003 Dec;26(4):317-30
pubmed: 14729134
Theranostics. 2020 Sep 14;10(24):11178-11196
pubmed: 33042277
Neurosci Lett. 2019 Jan 19;691:11-17
pubmed: 30099081
J Pharmacol Exp Ther. 2009 Nov;331(2):574-90
pubmed: 19661377
EJNMMI Radiopharm Chem. 2017;1(1):3
pubmed: 29564380
J Magn Reson Imaging. 2015 Nov;42(5):1431-40
pubmed: 26172043
Hum Brain Mapp. 2017 Jan;38(1):396-413
pubmed: 27627877
Transl Psychiatry. 2017 Mar 7;7(3):e1050
pubmed: 28267149
Pharmacol Rev. 2006 Sep;58(3):488-520
pubmed: 16968949
Trends Neurosci. 2019 Mar;42(3):205-220
pubmed: 30621912
Biol Psychiatry. 2017 Mar 15;81(6):525-535
pubmed: 27316853
Neuroimage. 2017 May 15;152:330-339
pubmed: 28254508
Nucl Med Biol. 2017 Dec;55:12-18
pubmed: 28972915
J Pharmacol Exp Ther. 2008 May;325(2):681-90
pubmed: 18287214
Neuropharmacology. 2008 Mar;54(4):745-54
pubmed: 18222493
Mol Psychiatry. 2011 Sep;16(9):885-6
pubmed: 21358709
J Histochem Cytochem. 2006 Nov;54(11):1205-13
pubmed: 16864896
Am J Psychiatry. 2016 Jul 1;173(7):714-21
pubmed: 26892941
J Neurochem. 2008 Apr;105(2):546-56
pubmed: 18088367
Biol Psychiatry. 2011 Jun 15;69(12):e113-25
pubmed: 21531388
Cereb Cortex. 2014 May;24(5):1165-77
pubmed: 23283687
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Curr Med Chem. 2013;20(3):351-6
pubmed: 23157626
Neuroimage. 2005 Oct 15;28(1):216-26
pubmed: 15979345
Transl Psychiatry. 2014 Apr 01;4:e376
pubmed: 24690597
Psychiatry Clin Neurosci. 2007 Dec;61(6):602-9
pubmed: 18081619
Neuropsychopharmacology. 2008 Jan;33(1):141-65
pubmed: 17805309
Hum Brain Mapp. 2021 Aug 15;42(12):4048-4058
pubmed: 34014611
JAMA Neurol. 2014 Dec;71(12):1520-8
pubmed: 25322077
Neuroimage. 1996 Dec;4(3 Pt 1):153-8
pubmed: 9345505
Neuron. 2002 Jan 31;33(3):341-55
pubmed: 11832223
Curr Biol. 2000 Jul 13;10(14):R509-11
pubmed: 10899013
NMR Biomed. 2019 Mar;32(3):e4058
pubmed: 30663818
Biol Psychiatry. 2021 Feb 1;89(3):270-277
pubmed: 33129486
Lancet Psychiatry. 2018 Oct;5(10):816-823
pubmed: 30236864
Med Res Rev. 2019 Sep;39(5):1892-1922
pubmed: 30740744